Database Study Shows Shorter Hospital Stay, Fewer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Database Study Shows Shorter Hospital Stay, Fewer Complications for Robotic-Assisted Prostate Surgery Versus Open Surgery

SUNNYVALE, Calif., Jan. 9, 2014 (GLOBE NEWSWIRE) -- New findings from a large, population-based study show that robotic-assisted radical prostatectomy (removal of the prostate and surrounding tissue) results in a shorter average hospital stay and lower overall complication rate compared to open surgery. Even in surgeons' initial robotic-assisted prostatectomy cases, robotic-assisted prostatectomies resulted in fewer complications and shorter hospital stays than open surgery. Researchers further documented that key proficiency measures, such as surgery time, complication rates and length of hospital stay, continued to improve as a surgeon's robotic-assisted case volume increased. Mean operating time remained longer for the robotic-assisted group. 1

This retrospective study also showed that open prostatectomies performed at multiple hospitals with a robotics program exhibited an overall lower complication rate than open prostatectomies performed at hospitals without a robotics program (15.8 percent versus 17.9 percent, respectively).

The authors indicate that limitations of the study include a lack of cost figures, functional outcomes, pathologic endpoints, and disease-free status, which therefore result in only a partial analysis of comparative effectiveness. In addition, unknown patient selection differences may exist between the open and robotic-assisted groups.

These results were published in the December 18 electronic edition of the Journal of Endourology .

Surgeons most commonly perform radical prostatectomy to treat prostate cancer in men expected to live for 10 or more years. 2 Prostate cancer is the most common cancer in men other than skin cancer, and approximately one man in six will be diagnosed with prostate cancer during his lifetime. 3

In this study, researchers used a patient database to identify 71,312 radical prostatectomies performed between 2004 and 2010 by 3,739 surgeons at more than 300 U.S. hospitals, using either open or robotic-assisted techniques. The study found that, compared to open prostatectomy, robotic-assisted radical prostatectomy was associated with a shorter average hospital stay, lower overall complication rate and fewer blood transfusions. These findings are summarized in the table below:

 
  Open Prostate Surgery (Non-Robotic Hospital) Open Prostate Surgery (Robotic Hospital) Robotic-Assisted Prostate Surgery
  n=13,840 n=30,124 n=27,348
Mean surgery time (hours) 3.2 3.4 4.4
Mean length of hospital stay (days) 3.7 3.4 2.2
Transfusion rate 17.1% (n=2,360) 11.5% (n=3,449) 2.3% (n=638)
Overall complications 17.9% (n=2,474) 15.8% (n=4,759) 10.6% (n=2,892)

P-values for parameters listed above between each group – robotic-assisted vs. open at robotic hospitals, robotic-assisted vs. open at non-robotic hospitals, and open at robotic vs. non-robotic hospitals – were statistically significant with p < 0.0001.

These results were evident even early in the learning curve.

"The study shows that even in the first 25 cases, robotic-assisted prostatectomies resulted in fewer complications and shorter hospital stays than open surgery," said Myriam Curet, MD, Chief Medical Advisor, Intuitive Surgical.

The study also found that as surgeons completed more robotic-assisted surgeries, there were decreases in overall surgery time, with less experienced surgeons averaging 5.0 hours for a case and more experienced surgeons averaging 3.9 hours. Decreases in complication rate (from 11.75 percent to 8.95 percent), and conversion rate (from 1.13 percent to 0.18 percent) were also found.

"Our analysis shows that outcomes of robotic-assisted radical prostatectomy improve as surgeons gain more experience with the procedure, and generally can be favorable relative to open surgery," said lead study author John W. Davis, M.D., of the MD Anderson Cancer Center in Houston.

Intuitive Surgical paid for access to the Premiere database and Axistat consulting services. Lead author Dr. Davis was reimbursed for travel expenses related to this study. Author Jessica Gabbert is employed by InClin (formerly Axistat). Author Usha Kreaden, Principal Biostatistician, is employed by Intuitive Surgical.

Important Information for Patients

All surgery presents risk, including da Vinci Surgery. Potential risks of any prostatectomy procedure may include but are not limited to urinary and/or sexual dysfunction due to nerve damage 4 , rectal or bowel injury 5 , blocked artery in the lung 5 , or blocked bowel 5 . Results, including cosmetic results, may vary.

Serious complications may occur in any surgery, up to and including death. Examples of serious and life-threatening complications, which may require hospitalization, include injury to tissues or organs, bleeding, infection, and internal scarring that can cause long-lasting dysfunction or pain. Temporary pain or nerve injury has been linked to the inverted position often used during abdominal and pelvic surgery. Patients should understand that risks of surgery include potential for human error and potential for equipment failure. Risks specific to minimally invasive surgery may include: a longer operative time, the need to convert the procedure to other surgical techniques, the need for additional or larger incision sites, a longer operation or longer time under anesthesia than your surgeon originally predicts. Converting to open surgery could mean a longer operative time, long time under anesthesia, and could lead to increased complications. Patients who bleed easily, have abnormal blood clotting, are pregnant or morbidly obese are typically not candidates for minimally invasive surgery, including da Vinci Surgery.

Other surgical approaches are available. Patients should review the risks of all surgical approaches and the risks of da Vinci procedures to decide if da Vinci Surgery is right for them. It is important to talk to your doctor about his/her surgical experience. For complete information on surgical risks, safety and indications for use, please refer to www.davincisurgery.com/safety .

About Intuitive Surgical, Inc.

Intuitive Surgical, Inc. (Nasdaq: ISRG ), headquartered in Sunnyvale, Calif., is the global leader in robotic-assisted, minimally invasive surgery. Intuitive Surgical develops, manufactures and markets the da Vinci ®  Surgical System. Intuitive Surgical's mission is to extend the benefits of minimally invasive surgery to those patients who can and should benefit from it.

About the  da Vinci   Surgical System

The  da Vinci  Surgical System is a surgical platform designed to enable complex surgery using a minimally invasive approach. The  da Vinci  Surgical System consists of an ergonomic surgeon console or consoles, a patient-side cart with three or four interactive arms, a high-performance vision system and proprietary  EndoWrist ®  instruments. Powered by state-of-the-art technology, the  da Vinci  Surgical System is designed to scale, filter and seamlessly translate the surgeon's hand movements into more precise movements of the  EndoWrist  instruments. The net result is an intuitive interface with improved surgical capabilities. By providing surgeons with superior visualization, enhanced dexterity, greater precision and ergonomic comfort, the  da Vinci  Surgical System makes it possible for skilled surgeons to perform more minimally invasive procedures involving complex dissection or reconstruction. For more information about clinical evidence related to  da Vinci  Surgery, please visit  www.intuitivesurgical.com/company/clinical-evidence/ .

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements comparing robotic-assisted prostatectomy procedures to prostatectomy procedures performed by open surgery. These forward-looking statements are necessarily estimates reflecting the best judgment of our management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements should, therefore, be considered in light of various important factors, including those under the heading "Risk Factors" in our annual report on Form 10-K for the year ended December 31, 2012, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Statements using words such as "estimates," "projects," "believes," "anticipates," "plans," "expects," "intends," "may," "will," "could," "should," "would," "targeted" and similar words and expressions are intended to identify forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. We undertake no obligation to publicly update or release any revisions to these forward-looking statements, except as required by law.

1  Davis J, Kreaden U, Gabbert J, Thomas R. Learning Curve Assessment of Robot-Assisted Radical Prostatectomy Compared to Open Surgery Controls from the Premier Perspective Database. J Endourol. 2013 Dec 18. [Epub ahead of print]

2  Medline Plus. Radical Prostatectomy. http://www.nlm.nih.gov/medlineplus/ency/article/007300.htm . Accessed November 13, 2013.

3  American Cancer Society. What are the key statistics about prostate cancer? American Cancer Society. http://www.cancer.org/cancer/prostatecancer/d...statistics . Last revised August 26, 2013. Accessed November 15, 2013.

4  Health Information and Quality Authority (HIQA), reporting to the Minister of Health-Ireland. Health technology assessment of robot-assisted surgery in selected surgical procedures, 21 September 2011.

5 Tewari A, Sooriakumaran P, Bloch DA, Seshadri-Kreaden U, Hebert AE, Wiklund P. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a systematic review and meta-analysis comparing retropubic, laparoscopic, and robotic prostatectomy. Eur Urol. 2012 Jul;62(1):1-15. Epub 2012 Feb 24

Intuitive Surgical Corporate Communications 408-523-7337

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 9

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 136

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 64

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 260

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 7

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 0

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 112

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 347

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 118

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 53

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading

Top 5 Most Recently Viewed Articles

What $1000 Invested in Nutanix 5 Years Ago Looks Like Now

Updated Category News Views 136

The Growth Journey of Nutanix Stock Nutanix (NASDAQ: NTNX) has shown impressive growth over the last five years, outpacing the market with an annualized return of 15.61%. With a current market capitalization exceeding $15.57 billion, the company has established itself as a significant player in the industry. Your Investment Potential If you were an investor who purchased...

Continue Reading
WANF Transitions to Independence, Strengthening Local News in Atlanta

Updated Category News Views 517

WANF Evolves into an Independent Television Station Gray Media's local television station WANF is embarking on an exciting new journey. Transitioning from more than three decades as a CBS affiliate, WANF will become an independent station, enabling it to better serve the Atlanta community. This strategic shift represents a significant opportunity to enhance the quality of...

Continue Reading
Monarch Quantum Poised for NASA’s Quantum Gravity Gradiometer

Updated Category News Views 228

Game Changer for Quantum Technology If you thought the quantum sector was crawling, buckle up. Monarch Quantum, Inc. just landed a huge gig—delivering its integrated Quantum Light Engines™ for NASA’s upcoming Quantum Gravity Gradiometer Pathfinder mission. That’s not just a feather in their cap; it’s a serious validation of their tech chops. This isn’t just...

Continue Reading
GLD and Mitchell & Ness: A Dynamic Retail Collaboration

Updated Category News Views 18

An Unlikely Fusion of Jewelry and Jerseys Here's a heads-up for you: two unlikely heavyweights, GLD from the world of jewelry and Mitchell & Ness from the land of sports nostalgia, have teamed up. Kicking things off back in May with the launch of Mitchell & Ness' new flagship in Philadelphia, they've designed a retail playground where style knows no bounds. Business in...

Continue Reading
NovoEd Hits Big: 14 Awards from Brandon Hall 2026

Updated Category News Views 17

Big Wins at the Brandon Hall HCM Awards You don't win 14 medals at a prestigious event like the Brandon Hall Group's HCM Excellence Awards without turning some heads. NovoEd, alongside industry giants 3M, Abbott, and Kohler, did just that in 2026. Talk about an impressive lineup. NovoEd's talent development tech is evidently hitting all the right notes across the board....

Continue Reading